411 related articles for article (PubMed ID: 29296692)
1. Targeted deep sequencing in polycythemia vera and essential thrombocythemia.
Tefferi A; Lasho TL; Guglielmelli P; Finke CM; Rotunno G; Elala Y; Pacilli A; Hanson CA; Pancrazzi A; Ketterling RP; Mannarelli C; Barraco D; Fanelli T; Pardanani A; Gangat N; Vannucchi AM
Blood Adv; 2016 Nov; 1(1):21-30. PubMed ID: 29296692
[TBL] [Abstract][Full Text] [Related]
2. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A; Barbui T
Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
[TBL] [Abstract][Full Text] [Related]
3. Targeted deep sequencing in primary myelofibrosis.
Tefferi A; Lasho TL; Finke CM; Elala Y; Hanson CA; Ketterling RP; Gangat N; Pardanani A
Blood Adv; 2016 Dec; 1(2):105-111. PubMed ID: 29296803
[TBL] [Abstract][Full Text] [Related]
4. Genetic Risk Assessment in Myeloproliferative Neoplasms.
Tefferi A; Vannucchi AM
Mayo Clin Proc; 2017 Aug; 92(8):1283-1290. PubMed ID: 28778261
[TBL] [Abstract][Full Text] [Related]
5. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
6. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera.
Delic S; Rose D; Kern W; Nadarajah N; Haferlach C; Haferlach T; Meggendorfer M
Br J Haematol; 2016 Nov; 175(3):419-426. PubMed ID: 27447873
[TBL] [Abstract][Full Text] [Related]
7. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
8. Prognostication in Philadelphia Chromosome Negative Myeloproliferative Neoplasms: a Review of the Recent Literature.
Zhou A; Afzal A; Oh ST
Curr Hematol Malig Rep; 2017 Oct; 12(5):397-405. PubMed ID: 28948488
[TBL] [Abstract][Full Text] [Related]
9. Targeted next-generation sequencing in blast phase myeloproliferative neoplasms.
Lasho TL; Mudireddy M; Finke CM; Hanson CA; Ketterling RP; Szuber N; Begna KH; Patnaik MM; Gangat N; Pardanani A; Tefferi A
Blood Adv; 2018 Feb; 2(4):370-380. PubMed ID: 29467191
[TBL] [Abstract][Full Text] [Related]
10. Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data.
Loscocco GG; Guglielmelli P; Vannucchi AM
Onco Targets Ther; 2020; 13():12367-12382. PubMed ID: 33293830
[TBL] [Abstract][Full Text] [Related]
11. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
Tefferi A
Am J Hematol; 2021 Jan; 96(1):145-162. PubMed ID: 33197049
[TBL] [Abstract][Full Text] [Related]
12. Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.
Tefferi A; Barbui T
Mayo Clin Proc; 2015 Sep; 90(9):1283-93. PubMed ID: 26355403
[TBL] [Abstract][Full Text] [Related]
13. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera.
Tefferi A; Guglielmelli P; Lasho TL; Coltro G; Finke CM; Loscocco GG; Sordi B; Szuber N; Rotunno G; Pacilli A; Hanson CA; Ketterling RP; Pardanani A; Gangat N; Vannucchi AM
Br J Haematol; 2020 Apr; 189(2):291-302. PubMed ID: 31945802
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL mutation.
Mannina D; Gagelmann N; Badbaran A; Ditschkowski M; Bogdanov R; Robin M; Cassinat B; Heuser M; Shahswar R; Thol F; Beelen D; Kröger N
Eur J Haematol; 2019 Dec; 103(6):552-557. PubMed ID: 31446640
[TBL] [Abstract][Full Text] [Related]
15. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2016 Dec; 91(12):1262-1271. PubMed ID: 27870387
[TBL] [Abstract][Full Text] [Related]
16. ASXL1 mutations in Chinese patients with essential thrombocythemia.
Nie YB; Sun M; He CK; Ju MK; Zhou FL; Wu SY; Zhou Y; Liu L; Shen H; Huang TT; Liu P; Xu Y; Shao L; Zuo XL
Exp Ther Med; 2018 May; 15(5):4149-4156. PubMed ID: 29725364
[TBL] [Abstract][Full Text] [Related]
17. Broad Next-Generation Integrated Sequencing of Myelofibrosis Identifies Disease-Specific and Age-Related Genomic Alterations.
Kandarpa M; Robinson D; Wu YM; Qin T; Pettit K; Li Q; Luker G; Sartor M; Chinnaiyan A; Talpaz M
Clin Cancer Res; 2024 May; 30(9):1972-1983. PubMed ID: 38386293
[TBL] [Abstract][Full Text] [Related]
18. Calreticulin exon 9 mutations in myeloproliferative neoplasms.
Ha JS; Kim YK
Ann Lab Med; 2015 Jan; 35(1):22-7. PubMed ID: 25553276
[TBL] [Abstract][Full Text] [Related]
19. Detection of CALR Mutation in Clonal and Nonclonal Hematologic Diseases Using Fragment Analysis and Next-Generation Sequencing.
Gardner JA; Peterson JD; Turner SA; Soares BL; Lancor CR; Dos Santos LL; Kaur P; Ornstein DL; Tsongalis GJ; de Abreu FB
Am J Clin Pathol; 2016 Oct; 146(4):448-55. PubMed ID: 27686171
[TBL] [Abstract][Full Text] [Related]
20. Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history.
Gangat N; Wassie EA; Lasho TL; Finke C; Ketterling RP; Hanson CA; Pardanani A; Wolanskyj AP; Maffioli M; Casalone R; Passamonti F; Tefferi A
Eur J Haematol; 2015 Jan; 94(1):31-6. PubMed ID: 24889737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
